nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ERBB4—melanoma	0.257	0.456	CbGaD
Lapatinib—ERBB2—melanoma	0.19	0.337	CbGaD
Lapatinib—EGFR—Docetaxel—melanoma	0.134	0.627	CbGbCtD
Lapatinib—EGFR—melanoma	0.0897	0.159	CbGaD
Lapatinib—ABCB1—melanoma	0.0273	0.0484	CbGaD
Lapatinib—CYP3A4—Temozolomide—melanoma	0.0254	0.119	CbGbCtD
Lapatinib—ABCB1—Dactinomycin—melanoma	0.0154	0.0723	CbGbCtD
Lapatinib—CYP3A4—Vemurafenib—melanoma	0.0139	0.0652	CbGbCtD
Lapatinib—CYP3A5—Docetaxel—melanoma	0.0123	0.0573	CbGbCtD
Lapatinib—ABCB1—Docetaxel—melanoma	0.00797	0.0373	CbGbCtD
Lapatinib—CYP3A4—Docetaxel—melanoma	0.00478	0.0224	CbGbCtD
Lapatinib—Metastatic disease—Docetaxel—melanoma	0.00312	0.0442	CcSEcCtD
Lapatinib—Metastatic neoplasm—Temozolomide—melanoma	0.00282	0.04	CcSEcCtD
Lapatinib—Metastatic neoplasm—Docetaxel—melanoma	0.00188	0.0266	CcSEcCtD
Lapatinib—Cardiotoxicity—Docetaxel—melanoma	0.00153	0.0216	CcSEcCtD
Lapatinib—Hepatotoxicity—Vemurafenib—melanoma	0.00137	0.0194	CcSEcCtD
Lapatinib—Neoplasm malignant—Vemurafenib—melanoma	0.00124	0.0176	CcSEcCtD
Lapatinib—Mucosal inflammation—Bleomycin—melanoma	0.00116	0.0164	CcSEcCtD
Lapatinib—Nail disorder—Bleomycin—melanoma	0.00099	0.014	CcSEcCtD
Lapatinib—ERBB2—neck—melanoma	0.000909	0.123	CbGeAlD
Lapatinib—Interstitial lung disease—Bleomycin—melanoma	0.000907	0.0128	CcSEcCtD
Lapatinib—Interstitial lung disease—Carmustine—melanoma	0.000792	0.0112	CcSEcCtD
Lapatinib—Hepatotoxicity—Dactinomycin—melanoma	0.000775	0.011	CcSEcCtD
Lapatinib—Pain in extremity—Vemurafenib—melanoma	0.000769	0.0109	CcSEcCtD
Lapatinib—Interstitial lung disease—Temozolomide—melanoma	0.000765	0.0108	CcSEcCtD
Lapatinib—TAP1—mammalian vulva—melanoma	0.000735	0.0997	CbGeAlD
Lapatinib—Hepatotoxicity—Carmustine—melanoma	0.000726	0.0103	CcSEcCtD
Lapatinib—Dry skin—Vemurafenib—melanoma	0.000705	0.00997	CcSEcCtD
Lapatinib—Hepatotoxicity—Temozolomide—melanoma	0.000701	0.00992	CcSEcCtD
Lapatinib—PIK3C2B—mammalian vulva—melanoma	0.00069	0.0936	CbGeAlD
Lapatinib—Gefitinib—EGFR—melanoma	0.000672	0.616	CrCbGaD
Lapatinib—Mucosal inflammation—Docetaxel—melanoma	0.00065	0.0092	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Temozolomide—melanoma	0.000595	0.00842	CcSEcCtD
Lapatinib—Infestation—Vemurafenib—melanoma	0.000593	0.00838	CcSEcCtD
Lapatinib—Infestation NOS—Vemurafenib—melanoma	0.000593	0.00838	CcSEcCtD
Lapatinib—ERBB2—skin of body—melanoma	0.000588	0.0798	CbGeAlD
Lapatinib—Neuropathy peripheral—Vemurafenib—melanoma	0.000581	0.00822	CcSEcCtD
Lapatinib—Nail disorder—Docetaxel—melanoma	0.000555	0.00785	CcSEcCtD
Lapatinib—Haemoglobin decreased—Docetaxel—melanoma	0.000523	0.0074	CcSEcCtD
Lapatinib—Connective tissue disorder—Vemurafenib—melanoma	0.000523	0.0074	CcSEcCtD
Lapatinib—Interstitial lung disease—Docetaxel—melanoma	0.000509	0.0072	CcSEcCtD
Lapatinib—PI4KB—mammalian vulva—melanoma	0.000503	0.0682	CbGeAlD
Lapatinib—Cardiac disorder—Vemurafenib—melanoma	0.000494	0.00699	CcSEcCtD
Lapatinib—PIK3C2B—head—melanoma	0.000494	0.067	CbGeAlD
Lapatinib—Angiopathy—Vemurafenib—melanoma	0.000483	0.00683	CcSEcCtD
Lapatinib—Mediastinal disorder—Vemurafenib—melanoma	0.000479	0.00678	CcSEcCtD
Lapatinib—Alopecia—Vemurafenib—melanoma	0.00047	0.00665	CcSEcCtD
Lapatinib—Hepatotoxicity—Docetaxel—melanoma	0.000466	0.0066	CcSEcCtD
Lapatinib—Malnutrition—Vemurafenib—melanoma	0.000463	0.00655	CcSEcCtD
Lapatinib—EGFR—mammalian vulva—melanoma	0.000455	0.0617	CbGeAlD
Lapatinib—Back pain—Vemurafenib—melanoma	0.000448	0.00634	CcSEcCtD
Lapatinib—Hot flush—Temozolomide—melanoma	0.00042	0.00594	CcSEcCtD
Lapatinib—Menopausal symptoms—Temozolomide—melanoma	0.000417	0.00589	CcSEcCtD
Lapatinib—Cough—Vemurafenib—melanoma	0.000404	0.00572	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Docetaxel—melanoma	0.000396	0.0056	CcSEcCtD
Lapatinib—Arthralgia—Vemurafenib—melanoma	0.000394	0.00558	CcSEcCtD
Lapatinib—Myalgia—Vemurafenib—melanoma	0.000394	0.00558	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000392	0.00554	CcSEcCtD
Lapatinib—ERBB2—head—melanoma	0.000384	0.0521	CbGeAlD
Lapatinib—ERBB4—head—melanoma	0.000384	0.0521	CbGeAlD
Lapatinib—Blood bilirubin increased—Docetaxel—melanoma	0.000381	0.00539	CcSEcCtD
Lapatinib—Anaphylactic shock—Vemurafenib—melanoma	0.000378	0.00535	CcSEcCtD
Lapatinib—Infection—Vemurafenib—melanoma	0.000375	0.00531	CcSEcCtD
Lapatinib—Nervous system disorder—Vemurafenib—melanoma	0.000371	0.00524	CcSEcCtD
Lapatinib—TAP1—lymph node—melanoma	0.000368	0.05	CbGeAlD
Lapatinib—Skin disorder—Vemurafenib—melanoma	0.000367	0.00519	CcSEcCtD
Lapatinib—Dehydration—Temozolomide—melanoma	0.000365	0.00517	CcSEcCtD
Lapatinib—Pneumonia—Bleomycin—melanoma	0.000361	0.00511	CcSEcCtD
Lapatinib—Dry skin—Temozolomide—melanoma	0.00036	0.0051	CcSEcCtD
Lapatinib—PI4KB—head—melanoma	0.00036	0.0488	CbGeAlD
Lapatinib—Neutropenia—Dactinomycin—melanoma	0.000351	0.00497	CcSEcCtD
Lapatinib—Stomatitis—Bleomycin—melanoma	0.00035	0.00495	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000347	0.0049	CcSEcCtD
Lapatinib—PIK3C2B—lymph node—melanoma	0.000346	0.0469	CbGeAlD
Lapatinib—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000344	0.00487	CcSEcCtD
Lapatinib—Pneumonia—Dactinomycin—melanoma	0.000337	0.00477	CcSEcCtD
Lapatinib—Neutropenia—Carmustine—melanoma	0.000329	0.00465	CcSEcCtD
Lapatinib—Decreased appetite—Vemurafenib—melanoma	0.000329	0.00465	CcSEcCtD
Lapatinib—Stomatitis—Dactinomycin—melanoma	0.000326	0.00462	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000326	0.00462	CcSEcCtD
Lapatinib—Fatigue—Vemurafenib—melanoma	0.000326	0.00461	CcSEcCtD
Lapatinib—Constipation—Vemurafenib—melanoma	0.000323	0.00457	CcSEcCtD
Lapatinib—Neutropenia—Temozolomide—melanoma	0.000318	0.00449	CcSEcCtD
Lapatinib—Pneumonia—Carmustine—melanoma	0.000315	0.00446	CcSEcCtD
Lapatinib—Neuropathy peripheral—Carmustine—melanoma	0.000307	0.00435	CcSEcCtD
Lapatinib—Stomatitis—Carmustine—melanoma	0.000305	0.00432	CcSEcCtD
Lapatinib—Pneumonia—Temozolomide—melanoma	0.000305	0.00431	CcSEcCtD
Lapatinib—Infestation—Temozolomide—melanoma	0.000303	0.00429	CcSEcCtD
Lapatinib—Infestation NOS—Temozolomide—melanoma	0.000303	0.00429	CcSEcCtD
Lapatinib—Neuropathy peripheral—Temozolomide—melanoma	0.000297	0.0042	CcSEcCtD
Lapatinib—Stomatitis—Temozolomide—melanoma	0.000295	0.00418	CcSEcCtD
Lapatinib—Hepatobiliary disease—Temozolomide—melanoma	0.000286	0.00405	CcSEcCtD
Lapatinib—Alopecia—Bleomycin—melanoma	0.000285	0.00403	CcSEcCtD
Lapatinib—Hot flush—Docetaxel—melanoma	0.000279	0.00395	CcSEcCtD
Lapatinib—Hypersensitivity—Vemurafenib—melanoma	0.000278	0.00394	CcSEcCtD
Lapatinib—Menopausal symptoms—Docetaxel—melanoma	0.000277	0.00392	CcSEcCtD
Lapatinib—Connective tissue disorder—Carmustine—melanoma	0.000276	0.00391	CcSEcCtD
Lapatinib—Asthenia—Vemurafenib—melanoma	0.000271	0.00384	CcSEcCtD
Lapatinib—ERBB2—lymph node—melanoma	0.000269	0.0365	CbGeAlD
Lapatinib—Cardiac failure—Docetaxel—melanoma	0.000268	0.00379	CcSEcCtD
Lapatinib—Pruritus—Vemurafenib—melanoma	0.000267	0.00378	CcSEcCtD
Lapatinib—Connective tissue disorder—Temozolomide—melanoma	0.000267	0.00378	CcSEcCtD
Lapatinib—Alopecia—Dactinomycin—melanoma	0.000266	0.00376	CcSEcCtD
Lapatinib—Pain in extremity—Docetaxel—melanoma	0.000261	0.0037	CcSEcCtD
Lapatinib—Anaemia—Bleomycin—melanoma	0.000259	0.00367	CcSEcCtD
Lapatinib—Diarrhoea—Vemurafenib—melanoma	0.000259	0.00366	CcSEcCtD
Lapatinib—Cardiac disorder—Temozolomide—melanoma	0.000252	0.00357	CcSEcCtD
Lapatinib—PI4KB—lymph node—melanoma	0.000252	0.0342	CbGeAlD
Lapatinib—Leukopenia—Bleomycin—melanoma	0.000251	0.00355	CcSEcCtD
Lapatinib—Alopecia—Carmustine—melanoma	0.000249	0.00352	CcSEcCtD
Lapatinib—Angiopathy—Temozolomide—melanoma	0.000247	0.00349	CcSEcCtD
Lapatinib—Mental disorder—Carmustine—melanoma	0.000246	0.00349	CcSEcCtD
Lapatinib—Immune system disorder—Temozolomide—melanoma	0.000246	0.00347	CcSEcCtD
Lapatinib—Mediastinal disorder—Temozolomide—melanoma	0.000245	0.00347	CcSEcCtD
Lapatinib—Malnutrition—Carmustine—melanoma	0.000245	0.00347	CcSEcCtD
Lapatinib—Cough—Bleomycin—melanoma	0.000245	0.00346	CcSEcCtD
Lapatinib—Dehydration—Docetaxel—melanoma	0.000243	0.00344	CcSEcCtD
Lapatinib—Anaemia—Dactinomycin—melanoma	0.000242	0.00342	CcSEcCtD
Lapatinib—Vomiting—Vemurafenib—melanoma	0.00024	0.0034	CcSEcCtD
Lapatinib—Alopecia—Temozolomide—melanoma	0.00024	0.0034	CcSEcCtD
Lapatinib—Dry skin—Docetaxel—melanoma	0.00024	0.00339	CcSEcCtD
Lapatinib—Myalgia—Bleomycin—melanoma	0.000239	0.00338	CcSEcCtD
Lapatinib—Rash—Vemurafenib—melanoma	0.000238	0.00337	CcSEcCtD
Lapatinib—Mental disorder—Temozolomide—melanoma	0.000238	0.00337	CcSEcCtD
Lapatinib—Dermatitis—Vemurafenib—melanoma	0.000238	0.00337	CcSEcCtD
Lapatinib—Back pain—Carmustine—melanoma	0.000237	0.00335	CcSEcCtD
Lapatinib—Headache—Vemurafenib—melanoma	0.000237	0.00335	CcSEcCtD
Lapatinib—Malnutrition—Temozolomide—melanoma	0.000237	0.00335	CcSEcCtD
Lapatinib—Leukopenia—Dactinomycin—melanoma	0.000234	0.00331	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Docetaxel—melanoma	0.000231	0.00326	CcSEcCtD
Lapatinib—Anaphylactic shock—Bleomycin—melanoma	0.000229	0.00324	CcSEcCtD
Lapatinib—Back pain—Temozolomide—melanoma	0.000229	0.00324	CcSEcCtD
Lapatinib—EGFR—lymph node—melanoma	0.000228	0.0309	CbGeAlD
Lapatinib—Infection—Bleomycin—melanoma	0.000227	0.00322	CcSEcCtD
Lapatinib—Anaemia—Carmustine—melanoma	0.000226	0.0032	CcSEcCtD
Lapatinib—Nausea—Vemurafenib—melanoma	0.000225	0.00318	CcSEcCtD
Lapatinib—Myalgia—Dactinomycin—melanoma	0.000223	0.00315	CcSEcCtD
Lapatinib—Leukopenia—Carmustine—melanoma	0.000219	0.0031	CcSEcCtD
Lapatinib—Anaemia—Temozolomide—melanoma	0.000219	0.0031	CcSEcCtD
Lapatinib—Anorexia—Bleomycin—melanoma	0.000218	0.00309	CcSEcCtD
Lapatinib—Gefitinib—ALB—melanoma	0.000214	0.196	CrCbGaD
Lapatinib—Infection—Dactinomycin—melanoma	0.000212	0.003	CcSEcCtD
Lapatinib—Leukopenia—Temozolomide—melanoma	0.000212	0.003	CcSEcCtD
Lapatinib—Neutropenia—Docetaxel—melanoma	0.000211	0.00299	CcSEcCtD
Lapatinib—Palpitations—Temozolomide—melanoma	0.000209	0.00296	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Bleomycin—melanoma	0.000209	0.00295	CcSEcCtD
Lapatinib—Myalgia—Carmustine—melanoma	0.000209	0.00295	CcSEcCtD
Lapatinib—Cough—Temozolomide—melanoma	0.000207	0.00292	CcSEcCtD
Lapatinib—Gefitinib—ABCB1—melanoma	0.000204	0.187	CrCbGaD
Lapatinib—Dyspnoea—Bleomycin—melanoma	0.000204	0.00289	CcSEcCtD
Lapatinib—Anorexia—Dactinomycin—melanoma	0.000204	0.00288	CcSEcCtD
Lapatinib—Pneumonia—Docetaxel—melanoma	0.000203	0.00287	CcSEcCtD
Lapatinib—Myalgia—Temozolomide—melanoma	0.000201	0.00285	CcSEcCtD
Lapatinib—Arthralgia—Temozolomide—melanoma	0.000201	0.00285	CcSEcCtD
Lapatinib—Infestation NOS—Docetaxel—melanoma	0.000201	0.00285	CcSEcCtD
Lapatinib—Infestation—Docetaxel—melanoma	0.000201	0.00285	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.0002	0.00283	CcSEcCtD
Lapatinib—Decreased appetite—Bleomycin—melanoma	0.000199	0.00282	CcSEcCtD
Lapatinib—Infection—Carmustine—melanoma	0.000199	0.00281	CcSEcCtD
Lapatinib—Neuropathy peripheral—Docetaxel—melanoma	0.000197	0.00279	CcSEcCtD
Lapatinib—Stomatitis—Docetaxel—melanoma	0.000196	0.00278	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000195	0.00275	CcSEcCtD
Lapatinib—Anaphylactic shock—Temozolomide—melanoma	0.000193	0.00273	CcSEcCtD
Lapatinib—Infection—Temozolomide—melanoma	0.000192	0.00272	CcSEcCtD
Lapatinib—Anorexia—Carmustine—melanoma	0.000191	0.0027	CcSEcCtD
Lapatinib—Hepatobiliary disease—Docetaxel—melanoma	0.00019	0.0027	CcSEcCtD
Lapatinib—Epistaxis—Docetaxel—melanoma	0.00019	0.00269	CcSEcCtD
Lapatinib—Nervous system disorder—Temozolomide—melanoma	0.000189	0.00268	CcSEcCtD
Lapatinib—Skin disorder—Temozolomide—melanoma	0.000188	0.00265	CcSEcCtD
Lapatinib—Decreased appetite—Dactinomycin—melanoma	0.000186	0.00263	CcSEcCtD
Lapatinib—Fatigue—Dactinomycin—melanoma	0.000184	0.00261	CcSEcCtD
Lapatinib—Anorexia—Temozolomide—melanoma	0.000184	0.00261	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Carmustine—melanoma	0.000182	0.00258	CcSEcCtD
Lapatinib—Insomnia—Carmustine—melanoma	0.000181	0.00256	CcSEcCtD
Lapatinib—Dyspnoea—Carmustine—melanoma	0.000178	0.00252	CcSEcCtD
Lapatinib—Connective tissue disorder—Docetaxel—melanoma	0.000178	0.00251	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Temozolomide—melanoma	0.000176	0.00249	CcSEcCtD
Lapatinib—Insomnia—Temozolomide—melanoma	0.000175	0.00247	CcSEcCtD
Lapatinib—Gastrointestinal pain—Dactinomycin—melanoma	0.000175	0.00247	CcSEcCtD
Lapatinib—Decreased appetite—Carmustine—melanoma	0.000174	0.00246	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Carmustine—melanoma	0.000173	0.00244	CcSEcCtD
Lapatinib—Dyspnoea—Temozolomide—melanoma	0.000172	0.00244	CcSEcCtD
Lapatinib—Constipation—Carmustine—melanoma	0.000171	0.00242	CcSEcCtD
Lapatinib—Dyspepsia—Temozolomide—melanoma	0.00017	0.00241	CcSEcCtD
Lapatinib—Abdominal pain—Dactinomycin—melanoma	0.000169	0.00239	CcSEcCtD
Lapatinib—Hypersensitivity—Bleomycin—melanoma	0.000169	0.00239	CcSEcCtD
Lapatinib—Decreased appetite—Temozolomide—melanoma	0.000168	0.00238	CcSEcCtD
Lapatinib—Cardiac disorder—Docetaxel—melanoma	0.000168	0.00237	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Temozolomide—melanoma	0.000167	0.00236	CcSEcCtD
Lapatinib—Fatigue—Temozolomide—melanoma	0.000167	0.00236	CcSEcCtD
Lapatinib—ABCB1—blood vessel—melanoma	0.000166	0.0225	CbGeAlD
Lapatinib—Constipation—Temozolomide—melanoma	0.000165	0.00234	CcSEcCtD
Lapatinib—Asthenia—Bleomycin—melanoma	0.000164	0.00232	CcSEcCtD
Lapatinib—Angiopathy—Docetaxel—melanoma	0.000164	0.00232	CcSEcCtD
Lapatinib—Gastrointestinal pain—Carmustine—melanoma	0.000163	0.00231	CcSEcCtD
Lapatinib—Immune system disorder—Docetaxel—melanoma	0.000163	0.00231	CcSEcCtD
Lapatinib—Mediastinal disorder—Docetaxel—melanoma	0.000163	0.00231	CcSEcCtD
Lapatinib—Pruritus—Bleomycin—melanoma	0.000162	0.00229	CcSEcCtD
Lapatinib—Alopecia—Docetaxel—melanoma	0.00016	0.00226	CcSEcCtD
Lapatinib—Mental disorder—Docetaxel—melanoma	0.000158	0.00224	CcSEcCtD
Lapatinib—Abdominal pain—Carmustine—melanoma	0.000158	0.00224	CcSEcCtD
Lapatinib—Gastrointestinal pain—Temozolomide—melanoma	0.000158	0.00223	CcSEcCtD
Lapatinib—Malnutrition—Docetaxel—melanoma	0.000157	0.00223	CcSEcCtD
Lapatinib—Hypersensitivity—Dactinomycin—melanoma	0.000157	0.00223	CcSEcCtD
Lapatinib—Asthenia—Dactinomycin—melanoma	0.000153	0.00217	CcSEcCtD
Lapatinib—Abdominal pain—Temozolomide—melanoma	0.000153	0.00216	CcSEcCtD
Lapatinib—Back pain—Docetaxel—melanoma	0.000152	0.00215	CcSEcCtD
Lapatinib—Hypersensitivity—Carmustine—melanoma	0.000147	0.00208	CcSEcCtD
Lapatinib—Diarrhoea—Dactinomycin—melanoma	0.000146	0.00207	CcSEcCtD
Lapatinib—Vomiting—Bleomycin—melanoma	0.000146	0.00206	CcSEcCtD
Lapatinib—Anaemia—Docetaxel—melanoma	0.000145	0.00206	CcSEcCtD
Lapatinib—Rash—Bleomycin—melanoma	0.000144	0.00204	CcSEcCtD
Lapatinib—Dermatitis—Bleomycin—melanoma	0.000144	0.00204	CcSEcCtD
Lapatinib—Asthenia—Carmustine—melanoma	0.000143	0.00203	CcSEcCtD
Lapatinib—Hypersensitivity—Temozolomide—melanoma	0.000142	0.00201	CcSEcCtD
Lapatinib—Leukopenia—Docetaxel—melanoma	0.000141	0.00199	CcSEcCtD
Lapatinib—Palpitations—Docetaxel—melanoma	0.000139	0.00197	CcSEcCtD
Lapatinib—Asthenia—Temozolomide—melanoma	0.000139	0.00196	CcSEcCtD
Lapatinib—Cough—Docetaxel—melanoma	0.000137	0.00194	CcSEcCtD
Lapatinib—Diarrhoea—Carmustine—melanoma	0.000137	0.00194	CcSEcCtD
Lapatinib—Pruritus—Temozolomide—melanoma	0.000137	0.00193	CcSEcCtD
Lapatinib—Nausea—Bleomycin—melanoma	0.000136	0.00192	CcSEcCtD
Lapatinib—Vomiting—Dactinomycin—melanoma	0.000136	0.00192	CcSEcCtD
Lapatinib—Rash—Dactinomycin—melanoma	0.000135	0.00191	CcSEcCtD
Lapatinib—Arthralgia—Docetaxel—melanoma	0.000134	0.0019	CcSEcCtD
Lapatinib—Myalgia—Docetaxel—melanoma	0.000134	0.0019	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000133	0.00188	CcSEcCtD
Lapatinib—Diarrhoea—Temozolomide—melanoma	0.000132	0.00187	CcSEcCtD
Lapatinib—Anaphylactic shock—Docetaxel—melanoma	0.000128	0.00182	CcSEcCtD
Lapatinib—Infection—Docetaxel—melanoma	0.000128	0.00181	CcSEcCtD
Lapatinib—Vomiting—Carmustine—melanoma	0.000127	0.0018	CcSEcCtD
Lapatinib—Nausea—Dactinomycin—melanoma	0.000127	0.00179	CcSEcCtD
Lapatinib—Rash—Carmustine—melanoma	0.000126	0.00178	CcSEcCtD
Lapatinib—Nervous system disorder—Docetaxel—melanoma	0.000126	0.00178	CcSEcCtD
Lapatinib—Dermatitis—Carmustine—melanoma	0.000126	0.00178	CcSEcCtD
Lapatinib—Headache—Carmustine—melanoma	0.000125	0.00177	CcSEcCtD
Lapatinib—Skin disorder—Docetaxel—melanoma	0.000125	0.00177	CcSEcCtD
Lapatinib—Vomiting—Temozolomide—melanoma	0.000123	0.00174	CcSEcCtD
Lapatinib—Anorexia—Docetaxel—melanoma	0.000122	0.00173	CcSEcCtD
Lapatinib—Rash—Temozolomide—melanoma	0.000122	0.00172	CcSEcCtD
Lapatinib—Dermatitis—Temozolomide—melanoma	0.000122	0.00172	CcSEcCtD
Lapatinib—Headache—Temozolomide—melanoma	0.000121	0.00171	CcSEcCtD
Lapatinib—Nausea—Carmustine—melanoma	0.000119	0.00168	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Docetaxel—melanoma	0.000117	0.00166	CcSEcCtD
Lapatinib—Insomnia—Docetaxel—melanoma	0.000116	0.00164	CcSEcCtD
Lapatinib—Nausea—Temozolomide—melanoma	0.000115	0.00162	CcSEcCtD
Lapatinib—Dyspnoea—Docetaxel—melanoma	0.000115	0.00162	CcSEcCtD
Lapatinib—Dyspepsia—Docetaxel—melanoma	0.000113	0.0016	CcSEcCtD
Lapatinib—Decreased appetite—Docetaxel—melanoma	0.000112	0.00158	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Docetaxel—melanoma	0.000111	0.00157	CcSEcCtD
Lapatinib—Fatigue—Docetaxel—melanoma	0.000111	0.00157	CcSEcCtD
Lapatinib—Constipation—Docetaxel—melanoma	0.00011	0.00155	CcSEcCtD
Lapatinib—Gastrointestinal pain—Docetaxel—melanoma	0.000105	0.00149	CcSEcCtD
Lapatinib—Abdominal pain—Docetaxel—melanoma	0.000102	0.00144	CcSEcCtD
Lapatinib—Hypersensitivity—Docetaxel—melanoma	9.46e-05	0.00134	CcSEcCtD
Lapatinib—Asthenia—Docetaxel—melanoma	9.22e-05	0.0013	CcSEcCtD
Lapatinib—Pruritus—Docetaxel—melanoma	9.09e-05	0.00129	CcSEcCtD
Lapatinib—Diarrhoea—Docetaxel—melanoma	8.79e-05	0.00124	CcSEcCtD
Lapatinib—ABCB1—retina—melanoma	8.73e-05	0.0118	CbGeAlD
Lapatinib—Vomiting—Docetaxel—melanoma	8.17e-05	0.00116	CcSEcCtD
Lapatinib—Rash—Docetaxel—melanoma	8.1e-05	0.00115	CcSEcCtD
Lapatinib—Dermatitis—Docetaxel—melanoma	8.09e-05	0.00114	CcSEcCtD
Lapatinib—Headache—Docetaxel—melanoma	8.05e-05	0.00114	CcSEcCtD
Lapatinib—Nausea—Docetaxel—melanoma	7.63e-05	0.00108	CcSEcCtD
Lapatinib—ABCB1—mammalian vulva—melanoma	6.99e-05	0.00949	CbGeAlD
Lapatinib—ABCB1—head—melanoma	5e-05	0.00679	CbGeAlD
Lapatinib—ABCB1—lymph node—melanoma	3.5e-05	0.00475	CbGeAlD
Lapatinib—EGFR—Adaptive Immune System—KRAS—melanoma	2.37e-06	1.65e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PDGFRA—melanoma	2.36e-06	1.64e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PHGDH—melanoma	2.35e-06	1.63e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LUM—melanoma	2.35e-06	1.63e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—FASN—melanoma	2.35e-06	1.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PRKCA—melanoma	2.34e-06	1.62e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ITGB3—melanoma	2.34e-06	1.62e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HRAS—melanoma	2.34e-06	1.62e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MAP2K1—melanoma	2.31e-06	1.61e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SLC5A5—melanoma	2.31e-06	1.6e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HPSE—melanoma	2.3e-06	1.6e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HRAS—melanoma	2.3e-06	1.6e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CD—melanoma	2.3e-06	1.6e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SPP1—melanoma	2.29e-06	1.59e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAP2K2—melanoma	2.29e-06	1.59e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CXCL8—melanoma	2.28e-06	1.58e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—IL6—melanoma	2.28e-06	1.58e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—PIK3CA—melanoma	2.27e-06	1.58e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.27e-06	1.57e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP17A1—melanoma	2.27e-06	1.57e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—VEGFA—melanoma	2.27e-06	1.57e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—BCL2—melanoma	2.26e-06	1.57e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CUBN—melanoma	2.26e-06	1.57e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—STAT3—melanoma	2.24e-06	1.56e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNG—melanoma	2.24e-06	1.56e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NRAS—melanoma	2.24e-06	1.55e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—IL6—melanoma	2.24e-06	1.55e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—AKT1—melanoma	2.24e-06	1.55e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.24e-06	1.55e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—VEGFA—melanoma	2.23e-06	1.55e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MDM2—melanoma	2.23e-06	1.55e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GNAQ—melanoma	2.23e-06	1.55e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CD44—melanoma	2.23e-06	1.55e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP17A1—melanoma	2.21e-06	1.54e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—STAT3—melanoma	2.21e-06	1.53e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	2.21e-06	1.53e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NRAS—melanoma	2.2e-06	1.53e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—IL6—melanoma	2.2e-06	1.53e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—AKT1—melanoma	2.2e-06	1.53e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—FGF2—melanoma	2.2e-06	1.53e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ERBB2—melanoma	2.2e-06	1.53e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SDHD—melanoma	2.18e-06	1.52e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—BSG—melanoma	2.18e-06	1.52e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CSPG4—melanoma	2.18e-06	1.52e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.18e-06	1.52e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL2—melanoma	2.18e-06	1.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—PIK3CA—melanoma	2.18e-06	1.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TERT—melanoma	2.17e-06	1.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CB—melanoma	2.17e-06	1.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—RAC1—melanoma	2.17e-06	1.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CD4—melanoma	2.17e-06	1.5e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.16e-06	1.5e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MAPK3—melanoma	2.14e-06	1.49e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GNA11—melanoma	2.14e-06	1.49e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP1B1—melanoma	2.14e-06	1.48e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GPAM—melanoma	2.11e-06	1.47e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MAPK3—melanoma	2.11e-06	1.47e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HRAS—melanoma	2.1e-06	1.46e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—AKT1—melanoma	2.1e-06	1.46e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—FASN—melanoma	2.09e-06	1.45e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GNA11—melanoma	2.09e-06	1.45e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MYC—melanoma	2.08e-06	1.45e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HIF1A—melanoma	2.08e-06	1.44e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—AKT1—melanoma	2.06e-06	1.43e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SLC5A5—melanoma	2.06e-06	1.43e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MDM2—melanoma	2.06e-06	1.43e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MYC—melanoma	2.05e-06	1.43e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	2.05e-06	1.42e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—FASN—melanoma	2.04e-06	1.42e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MAPK1—melanoma	2.04e-06	1.42e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—EGFR—melanoma	2.04e-06	1.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDKN1B—melanoma	2.04e-06	1.41e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—AKT1—melanoma	2.03e-06	1.41e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ABCB1—melanoma	2.03e-06	1.41e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—ERBB2—melanoma	2.03e-06	1.41e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HRAS—melanoma	2.02e-06	1.4e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IL6—melanoma	2.01e-06	1.4e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SLC5A5—melanoma	2.01e-06	1.4e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MAPK1—melanoma	2.01e-06	1.39e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—EGFR—melanoma	2.01e-06	1.39e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CB—melanoma	2e-06	1.39e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CD4—melanoma	2e-06	1.39e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL2—melanoma	1.99e-06	1.38e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GNAQ—melanoma	1.99e-06	1.38e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CD44—melanoma	1.99e-06	1.38e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KDR—melanoma	1.99e-06	1.38e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—melanoma	1.99e-06	1.38e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.95e-06	1.35e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GNAQ—melanoma	1.94e-06	1.35e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CD44—melanoma	1.94e-06	1.35e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.93e-06	1.34e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KRAS—melanoma	1.93e-06	1.34e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CTNNB1—melanoma	1.92e-06	1.34e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FN1—melanoma	1.91e-06	1.33e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP1B1—melanoma	1.91e-06	1.32e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KRAS—melanoma	1.9e-06	1.32e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.89e-06	1.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDKN1B—melanoma	1.88e-06	1.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDKN1A—melanoma	1.88e-06	1.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PTEN—melanoma	1.88e-06	1.3e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOTCH1—melanoma	1.87e-06	1.3e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PRKCA—melanoma	1.87e-06	1.3e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NFKB1—melanoma	1.87e-06	1.3e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP1B1—melanoma	1.86e-06	1.29e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT1—melanoma	1.86e-06	1.29e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ERCC2—melanoma	1.85e-06	1.29e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CD80—melanoma	1.83e-06	1.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APC—melanoma	1.83e-06	1.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CG—melanoma	1.83e-06	1.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KIT—melanoma	1.83e-06	1.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—NRAS—melanoma	1.83e-06	1.27e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—EGF—melanoma	1.81e-06	1.26e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PLA2G6—melanoma	1.8e-06	1.25e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT1—melanoma	1.78e-06	1.24e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CTNNB1—melanoma	1.78e-06	1.23e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PIK3CA—melanoma	1.77e-06	1.23e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ABCB1—melanoma	1.76e-06	1.22e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—MAPK3—melanoma	1.75e-06	1.22e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PIK3CA—melanoma	1.74e-06	1.21e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDKN1A—melanoma	1.74e-06	1.21e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTEN—melanoma	1.73e-06	1.2e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—BRAF—melanoma	1.72e-06	1.2e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—melanoma	1.71e-06	1.19e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—melanoma	1.69e-06	1.17e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.68e-06	1.17e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—STAT3—melanoma	1.68e-06	1.16e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IGF1—melanoma	1.68e-06	1.16e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NRAS—melanoma	1.67e-06	1.16e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—MAPK1—melanoma	1.67e-06	1.16e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HRAS—melanoma	1.64e-06	1.14e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAP2K1—melanoma	1.62e-06	1.13e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PRKCA—melanoma	1.62e-06	1.12e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—VCAN—melanoma	1.62e-06	1.12e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HRAS—melanoma	1.61e-06	1.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CD—melanoma	1.61e-06	1.12e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ERCC2—melanoma	1.61e-06	1.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK3—melanoma	1.6e-06	1.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—KRAS—melanoma	1.58e-06	1.09e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ABCB1—melanoma	1.57e-06	1.09e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—melanoma	1.57e-06	1.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—STAT3—melanoma	1.55e-06	1.08e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NRAS—melanoma	1.54e-06	1.07e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—melanoma	1.54e-06	1.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FGF2—melanoma	1.54e-06	1.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MAPK1—melanoma	1.52e-06	1.06e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MAPK3—melanoma	1.48e-06	1.03e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CG—melanoma	1.46e-06	1.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CA—melanoma	1.45e-06	1.01e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PRKCA—melanoma	1.45e-06	1e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT1—melanoma	1.45e-06	1e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MDM2—melanoma	1.44e-06	1e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KRAS—melanoma	1.44e-06	1e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MYC—melanoma	1.44e-06	9.99e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ERCC2—melanoma	1.43e-06	9.96e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT1—melanoma	1.42e-06	9.89e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ERBB2—melanoma	1.42e-06	9.87e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPARG—melanoma	1.41e-06	9.82e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PRKCA—melanoma	1.41e-06	9.8e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—MAPK1—melanoma	1.41e-06	9.77e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CB—melanoma	1.4e-06	9.74e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ERCC2—melanoma	1.4e-06	9.72e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP17A1—melanoma	1.36e-06	9.46e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL8—melanoma	1.35e-06	9.36e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—HRAS—melanoma	1.34e-06	9.3e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.33e-06	9.24e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—KRAS—melanoma	1.33e-06	9.23e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CA—melanoma	1.32e-06	9.19e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDKN1B—melanoma	1.32e-06	9.14e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CASP3—melanoma	1.29e-06	8.96e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL2—melanoma	1.29e-06	8.95e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CD—melanoma	1.29e-06	8.94e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GNA11—melanoma	1.29e-06	8.94e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—melanoma	1.28e-06	8.9e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ALB—melanoma	1.27e-06	8.83e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CG—melanoma	1.27e-06	8.81e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—FASN—melanoma	1.26e-06	8.75e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCND1—melanoma	1.26e-06	8.72e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CTNNB1—melanoma	1.24e-06	8.64e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC5A5—melanoma	1.24e-06	8.6e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPARG—melanoma	1.22e-06	8.5e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HRAS—melanoma	1.22e-06	8.5e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CA—melanoma	1.22e-06	8.48e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—melanoma	1.22e-06	8.47e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDKN1A—melanoma	1.22e-06	8.44e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTEN—melanoma	1.21e-06	8.42e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NFKB1—melanoma	1.21e-06	8.38e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GNAQ—melanoma	1.2e-06	8.31e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CD44—melanoma	1.2e-06	8.31e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.19e-06	8.25e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT1—melanoma	1.18e-06	8.21e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—melanoma	1.17e-06	8.13e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP1B1—melanoma	1.15e-06	7.97e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CG—melanoma	1.13e-06	7.86e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—HRAS—melanoma	1.13e-06	7.85e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CB—melanoma	1.12e-06	7.79e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CD—melanoma	1.12e-06	7.75e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—melanoma	1.11e-06	7.72e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CG—melanoma	1.11e-06	7.68e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ALB—melanoma	1.1e-06	7.65e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—melanoma	1.1e-06	7.6e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPARG—melanoma	1.09e-06	7.59e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STAT3—melanoma	1.08e-06	7.53e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NRAS—melanoma	1.08e-06	7.51e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—melanoma	1.08e-06	7.51e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT1—melanoma	1.08e-06	7.5e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPARG—melanoma	1.07e-06	7.41e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK3—melanoma	1.04e-06	7.19e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MYC—melanoma	1.01e-06	7e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT1—melanoma	9.98e-07	6.93e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CD—melanoma	9.95e-07	6.91e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAPK1—melanoma	9.86e-07	6.84e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ALB—melanoma	9.83e-07	6.82e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CB—melanoma	9.72e-07	6.75e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CD—melanoma	9.72e-07	6.75e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTEN—melanoma	9.7e-07	6.73e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—melanoma	9.63e-07	6.69e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ALB—melanoma	9.59e-07	6.66e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCB1—melanoma	9.45e-07	6.56e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KRAS—melanoma	9.31e-07	6.46e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PRKCA—melanoma	8.69e-07	6.04e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CB—melanoma	8.68e-07	6.03e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ERCC2—melanoma	8.62e-07	5.99e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—melanoma	8.6e-07	5.97e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CA—melanoma	8.55e-07	5.94e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CB—melanoma	8.47e-07	5.88e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTEN—melanoma	8.4e-07	5.83e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—melanoma	8.39e-07	5.83e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—melanoma	8.27e-07	5.75e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HRAS—melanoma	7.91e-07	5.5e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—melanoma	7.57e-07	5.26e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTEN—melanoma	7.5e-07	5.21e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTEN—melanoma	7.32e-07	5.08e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT1—melanoma	6.99e-07	4.85e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CA—melanoma	6.84e-07	4.75e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CG—melanoma	6.81e-07	4.73e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPARG—melanoma	6.57e-07	4.56e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CD—melanoma	5.99e-07	4.16e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CA—melanoma	5.93e-07	4.12e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ALB—melanoma	5.91e-07	4.1e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKT1—melanoma	5.59e-07	3.88e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CA—melanoma	5.29e-07	3.67e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CB—melanoma	5.22e-07	3.62e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—melanoma	5.17e-07	3.59e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CA—melanoma	5.16e-07	3.59e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKT1—melanoma	4.84e-07	3.36e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTEN—melanoma	4.51e-07	3.13e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKT1—melanoma	4.32e-07	3e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKT1—melanoma	4.22e-07	2.93e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CA—melanoma	3.18e-07	2.21e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKT1—melanoma	2.6e-07	1.8e-06	CbGpPWpGaD
